Patents by Inventor Melissa C. Whiteman

Melissa C. Whiteman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • A VIRUS NEUTRALIZATION ASSAY UTILIZING IMAGING CYTOMETRY
    Publication number: 20210293818
    Abstract: The instant invention describes a virus reduction neutralization test (VRNT) which is a rapid, high throughput alternative to current standard low throughput and laborious neutralization assays. The VRNT utilizes imaging cytometry to count virus-infected cells at about one day post-infection (thus eliminating the wait time other assays employ allowing for viral infection cell to cell), reducing overall assay time and increasing throughput at least 15-fold.
    Type: Application
    Filed: August 9, 2019
    Publication date: September 23, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Melissa C. Whiteman, Joseph M. Antonello, Leah A. Bogardus, Danila G. Giacone, Dengyun Sun, Amy H.M. Tou, Kevin B. Gurney, Leonard J. Rubinstein
  • Attenuated virus strains and uses thereof
    Patent number: 8017754
    Abstract: Methods and compositions concerning mutant flaviviruses with reduced virulence. In some embodiments the invention concerns nucleotide sequences that encode mutant flaviviral proteins. Viruses comprising mutant NS1 and NS4B genes display reduced virulence are provided. In further aspects of the invention, flavivirus vaccine compositions such as West Nile virus vaccines are provided. In another embodiment the invention provides methods for vaccination against flavivirus infection.
    Type: Grant
    Filed: July 14, 2006
    Date of Patent: September 13, 2011
    Assignee: Research Development Foundation
    Inventors: Jason A. Wicker, Melissa C. Whiteman, Michael D. T. Barrett
  • NOVEL ATTENUATED VIRUS STRAINS AND USES THEREOF
    Publication number: 20090117149
    Abstract: Methods and compositions concerning mutant flaviviruses with reduced virulence. In some embodiments the invention concerns nucleotide sequences that encode mutant flaviviral proteins. Viruses comprising mutant NS1 and NS4B genes display reduced virulence are provided. In further aspects of the invention, flavivirus vaccine compositions such as West Nile virus vaccines are provided. In another embodiment the invention provides methods for vaccination against flavivirus infection.
    Type: Application
    Filed: July 14, 2006
    Publication date: May 7, 2009
    Applicant: Research Development Foundation
    Inventors: Jason A. Wicker, Melissa C. Whiteman, Alan D.T. Barrett